Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2–mediated angiogenesis
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 12 (1) , 82
Abstract
Anti-angiogenesis targeting VEGFR2 has been considered as an important strategy for cancer therapy. Tylophorine is known to possess anti-inflammatory and antitumor activity, but its roles in tumor angiogenesis, the key step involved in tumor growth and metastasis, and the involved molecular mechanism is still unknown. Therefore, we examined its anti-angiogenic effects and mechanisms in vitro and in vivo.Keywords
This publication has 62 references indexed in Scilit:
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Vascular endothelial growth factor receptor-2 in breast cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Acetyl-11-Keto-β-Boswellic Acid Inhibits Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2–Mediated AngiogenesisCancer Research, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activityProceedings of the National Academy of Sciences, 2008
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Vascular Endothelial Growth Factor and AngiogenesisPharmacological Reviews, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003